首页 > 最新文献

Journal of Research in Pharmacy Practice最新文献

英文 中文
Strategic Role and Challenges of Community Pharmacists in SARS-CoV-2 Outbreak. 社区药师在SARS-CoV-2疫情中的战略作用与挑战
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-05-13 eCollection Date: 2021-01-01 DOI: 10.4103/jrpp.JRPP_20_131
Debjyoti Talukdar, Satish Jankie, Shyam Sundar Pancholi, Arindam Chatterjee, Parveen Kumar, Madan Mohan Gupta

This study highlights the importance of community pharmacists' strategic role in hindering the progression of the SARS-CoV-2 virus in the community setting and innovative measures to protect themselves. This article focuses on the features, control, and prevention of COVID-19 and social awareness measures of the pandemic. The means employed by the community pharmacist to safeguard his health while providing pharmaceutical services during COVID-19 is compiled and presented to benefit health-care professionals around the world. As per the US Center for Disease Control and Prevention, community pharmacists play a crucial role in providing essential drugs to patients without knowing their current COVID-19 status. They also work in conditions that make them susceptible to COVID-19 exposure. Despite the availability of guidelines, community pharmacists need to be trained in personal protective equipment for efficient protection and prevention of spread. Community pharmacists are essential frontline warriors against transmission of the SARS-CoV-2 virus in the community and act as frontline workers to educate the public on COVID-19. They are at high risk and need to observe necessary precautions to mitigate the spread of the virus.

这项研究强调了社区药剂师在社区环境中阻碍严重急性呼吸系统综合征冠状病毒2型病毒发展的战略作用以及保护自己的创新措施的重要性。本文重点介绍了新冠肺炎的特点、控制和预防以及社会对新冠肺炎的认识措施。在新冠肺炎期间,社区药剂师在提供药物服务的同时,为保护自己的健康而采用的方法被汇编和介绍,以造福世界各地的医疗保健专业人员。根据美国疾病控制和预防中心的说法,社区药剂师在不知道患者当前新冠肺炎状况的情况下,为患者提供基本药物方面发挥着至关重要的作用。他们也在容易接触新冠肺炎的条件下工作。尽管有指导方针,但社区药剂师需要接受个人防护设备方面的培训,以有效保护和防止传播。社区药剂师是防止SARS-CoV-2病毒在社区传播的重要前线战士,也是教育公众了解新冠肺炎的一线工作者。他们的风险很高,需要采取必要的预防措施来减缓病毒的传播。
{"title":"Strategic Role and Challenges of Community Pharmacists in SARS-CoV-2 Outbreak.","authors":"Debjyoti Talukdar,&nbsp;Satish Jankie,&nbsp;Shyam Sundar Pancholi,&nbsp;Arindam Chatterjee,&nbsp;Parveen Kumar,&nbsp;Madan Mohan Gupta","doi":"10.4103/jrpp.JRPP_20_131","DOIUrl":"10.4103/jrpp.JRPP_20_131","url":null,"abstract":"<p><p>This study highlights the importance of community pharmacists' strategic role in hindering the progression of the SARS-CoV-2 virus in the community setting and innovative measures to protect themselves. This article focuses on the features, control, and prevention of COVID-19 and social awareness measures of the pandemic. The means employed by the community pharmacist to safeguard his health while providing pharmaceutical services during COVID-19 is compiled and presented to benefit health-care professionals around the world. As per the US Center for Disease Control and Prevention, community pharmacists play a crucial role in providing essential drugs to patients without knowing their current COVID-19 status. They also work in conditions that make them susceptible to COVID-19 exposure. Despite the availability of guidelines, community pharmacists need to be trained in personal protective equipment for efficient protection and prevention of spread. Community pharmacists are essential frontline warriors against transmission of the SARS-CoV-2 virus in the community and act as frontline workers to educate the public on COVID-19. They are at high risk and need to observe necessary precautions to mitigate the spread of the virus.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 1","pages":"1-9"},"PeriodicalIF":1.0,"publicationDate":"2021-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/9f/JRPP-10-1.PMC8259598.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39210675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Clinical Characteristics, Medication Prescription Pattern, and Treatment Outcomes at the Neonatal Intensive Care Unit of a Tertiary Health-Care Facility in Ghana. 加纳一家三级医疗机构新生儿重症监护室的临床特征、药物处方模式和治疗效果。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-05-13 eCollection Date: 2021-01-01 DOI: 10.4103/jrpp.JRPP_20_118
Kwame Opare-Asamoah, George Asumeng Koffuor, Alhassan Abdul-Mumin, Baba Mohammed Sulemana, Majeed Saeed, Lawrence Quaye

Objective: Neonates are more susceptible to infections, as well as medication toxicities. This study, therefore, sought to describe the clinical characteristics, medication prescription pattern, and treatment outcomes for neonates admitted to the neonatal intensive care unit (NICU) of a tertiary health-care facility in Ghana.

Methods: A retrospective cross-sectional study was conducted to ascertain clinical records, conditions for admission, spectrum of medications prescribed, and treatment outcomes from neonatal patient folders.

Findings: Of 667 folders reviewed (51.4% males and 48.6% female), 61.8% were preterm (mean gestational age: 34.2 ± 3.6 weeks), 64.6% had low birth weight (LBW) (mean birth weight: 2.1 ± 0.9 kg), 90.6% were delivered through spontaneous vaginal delivery, and 57.4% delivered at the tertiary health-care facility. Of the 667 neonates, 70%, 27.1%, and 2.9% were queried with one, two, or three medical conditions, respectively. Respiratory distress, preterm, and pyrexia were common single queried conditions (88.5%). LBW, hypothermia, and single queried medical conditions were associated (P ≤ 0.0001) with preterm male neonates. The mean duration of stay of preterm neonates was 3.5 ± 3.2 days (term babies: 1-2 days [P = 0.0085]). Of 1,565 medications prescribed to the 667 neonates, 67.5% were antibacterial, with gentamicin (53.0%) being the most prescribed. 98.4% of neonates were prescribed at least one medication (i.e., 67.5% were prescribed antibacterial medications, 14.6% supplements, 11.0% bronchodilators, and 7.0% antiseizure); mean medication combination 2.6 ± 0.8 per neonate. Majority (75.4%) of the cases reviewed had treatment success.

Conclusion: Respiratory distress and preterm deliveries are predominant presenting conditions, with antibacterial medication, mainly gentamicin and ampicillin, on prescription. Treatment success is significantly high at the NICU.

目的:新生儿更容易受到感染和药物毒性的影响。因此,本研究试图描述加纳一家三级医疗机构新生儿重症监护室(NICU)收治的新生儿的临床特征、处方用药模式和治疗结果:方法:进行了一项回顾性横断面研究,从新生儿患者文件夹中确定临床记录、入院条件、处方药物范围和治疗结果:在接受审查的 667 份病历中(51.4% 为男性,48.6% 为女性),61.8% 为早产儿(平均胎龄:34.2 ± 3.6 周),64.6% 为低出生体重儿(LBW)(平均出生体重:2.1 ± 0.9 千克),90.6% 经阴道自然分娩,57.4% 在三级医疗机构分娩。在 667 名新生儿中,分别有 70%、27.1% 和 2.9% 的新生儿患有一种、两种或三种疾病。呼吸窘迫、早产和热病是常见的单一病症(88.5%)。低体重儿、体温过低和单一病症与早产男婴有关(P ≤ 0.0001)。早产新生儿的平均住院时间为 3.5 ± 3.2 天(足月儿:1-2 天 [P = 0.0085])。在为 667 名新生儿开出的 1,565 种药物中,67.5% 是抗菌药物,其中庆大霉素(53.0%)是开出最多的药物。98.4%的新生儿至少被处方了一种药物(即67.5%被处方了抗菌药物,14.6%被处方了补充剂,11.0%被处方了支气管扩张剂,7.0%被处方了抗癫痫药物);每个新生儿的平均药物组合为2.6 ± 0.8。大多数病例(75.4%)治疗成功:结论:呼吸窘迫和早产是主要的发病原因,处方中的抗菌药物主要是庆大霉素和氨苄西林。新生儿重症监护室的治疗成功率很高。
{"title":"Clinical Characteristics, Medication Prescription Pattern, and Treatment Outcomes at the Neonatal Intensive Care Unit of a Tertiary Health-Care Facility in Ghana.","authors":"Kwame Opare-Asamoah, George Asumeng Koffuor, Alhassan Abdul-Mumin, Baba Mohammed Sulemana, Majeed Saeed, Lawrence Quaye","doi":"10.4103/jrpp.JRPP_20_118","DOIUrl":"10.4103/jrpp.JRPP_20_118","url":null,"abstract":"<p><strong>Objective: </strong>Neonates are more susceptible to infections, as well as medication toxicities. This study, therefore, sought to describe the clinical characteristics, medication prescription pattern, and treatment outcomes for neonates admitted to the neonatal intensive care unit (NICU) of a tertiary health-care facility in Ghana.</p><p><strong>Methods: </strong>A retrospective cross-sectional study was conducted to ascertain clinical records, conditions for admission, spectrum of medications prescribed, and treatment outcomes from neonatal patient folders.</p><p><strong>Findings: </strong>Of 667 folders reviewed (51.4% males and 48.6% female), 61.8% were preterm (mean gestational age: 34.2 ± 3.6 weeks), 64.6% had low birth weight (LBW) (mean birth weight: 2.1 ± 0.9 kg), 90.6% were delivered through spontaneous vaginal delivery, and 57.4% delivered at the tertiary health-care facility. Of the 667 neonates, 70%, 27.1%, and 2.9% were queried with one, two, or three medical conditions, respectively. Respiratory distress, preterm, and pyrexia were common single queried conditions (88.5%). LBW, hypothermia, and single queried medical conditions were associated (<i>P</i> ≤ 0.0001) with preterm male neonates. The mean duration of stay of preterm neonates was 3.5 ± 3.2 days (term babies: 1-2 days [<i>P</i> = 0.0085]). Of 1,565 medications prescribed to the 667 neonates, 67.5% were antibacterial, with gentamicin (53.0%) being the most prescribed. 98.4% of neonates were prescribed at least one medication (i.e., 67.5% were prescribed antibacterial medications, 14.6% supplements, 11.0% bronchodilators, and 7.0% antiseizure); mean medication combination 2.6 ± 0.8 per neonate. Majority (75.4%) of the cases reviewed had treatment success.</p><p><strong>Conclusion: </strong>Respiratory distress and preterm deliveries are predominant presenting conditions, with antibacterial medication, mainly gentamicin and ampicillin, on prescription. Treatment success is significantly high at the NICU.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 1","pages":"30-37"},"PeriodicalIF":1.0,"publicationDate":"2021-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/88/JRPP-10-30.PMC8259601.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39210679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring Cypriot Pharmacists' Perceptions about their Role in Cardiovascular Disease Prevention: A Descriptive Qualitative Study. 探索塞浦路斯药剂师对他们在心血管疾病预防中的作用的看法:一项描述性质的研究。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-05-13 eCollection Date: 2021-01-01 DOI: 10.4103/jrpp.JRPP_20_102
Periklis Charalampous, Aliki Peletidi

Objective: The age-standardized prevalence of cardiovascular diseases (CVDs) among the Cypriot population in 2017 was estimated to be 5552 per 100,000. Therefore, the CVD prevention in Cyprus is of paramount importance. Pharmacists are one of the most accessible health-care professionals (HCPs) and the first port of call for the public. In Cyprus, there are 55.59 pharmacies per 100,000 inhabitants. Therefore, the role of Cypriot pharmacists (CPs) in primary CVD prevention is essential. This study aimed to explore both the existing and potential future roles of CPs in CVD prevention.

Methods: A descriptive qualitative study employing structured interviews (SIs) was conducted. Initially, the CPs were identified through a list provided by the Cypriot Pharmaceutical Services. The researcher(s) then contacted CPs by telephone. Face-to-face interviews were scheduled based on the CP's availability. In total, 21 SIs were transcribed verbatim, coded, and analyzed thematically. SIs continued until data saturation was achieved.

Findings: The findings are reported under the themes of pharmacists' knowledge and role, resources/tools available and training, communication and relations, and barriers. CPs expressed the need for training, and they are ready to have a more proactive role within the primary health care. The main barrier identified was the lack of responsiveness of the public and the lack of CP's time.

Conclusion: CPs have the potential to actively participate in CVD prevention in Cyprus. CPs want to start offering primary CVD health services, with the smoking cessation being the first intervention.

目的:2017年塞浦路斯人口中心血管疾病(cvd)的年龄标准化患病率估计为每10万人5552人。因此,塞浦路斯的心血管疾病预防至关重要。药剂师是最容易获得的卫生保健专业人员(HCPs)之一,也是公众的第一站。在塞浦路斯,每10万居民有55.59家药店。因此,塞浦路斯药剂师(CPs)在初级心血管疾病预防中的作用是必不可少的。本研究旨在探讨CPs在心血管疾病预防中的现有作用和潜在的未来作用。方法:采用结构化访谈法进行描述性质的研究。最初,通过塞浦路斯医药服务处提供的一份清单确定了这些药物。研究人员随后通过电话与CPs联系。面对面的面谈是根据CP的时间安排的。总共有21个si被逐字转录、编码并进行主题分析。si一直持续到数据饱和。调查结果:调查结果以药师的知识和作用、可用资源/工具和培训、沟通和关系以及障碍为主题进行报告。专科医生表示需要培训,他们准备在初级卫生保健中发挥更积极主动的作用。确定的主要障碍是公众缺乏反应和CP缺乏时间。结论:在塞浦路斯,CPs具有积极参与心血管疾病预防的潜力。CPs希望开始提供初级心血管疾病健康服务,戒烟是第一个干预措施。
{"title":"Exploring Cypriot Pharmacists' Perceptions about their Role in Cardiovascular Disease Prevention: A Descriptive Qualitative Study.","authors":"Periklis Charalampous,&nbsp;Aliki Peletidi","doi":"10.4103/jrpp.JRPP_20_102","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_20_102","url":null,"abstract":"<p><strong>Objective: </strong>The age-standardized prevalence of cardiovascular diseases (CVDs) among the Cypriot population in 2017 was estimated to be 5552 per 100,000. Therefore, the CVD prevention in Cyprus is of paramount importance. Pharmacists are one of the most accessible health-care professionals (HCPs) and the first port of call for the public. In Cyprus, there are 55.59 pharmacies per 100,000 inhabitants. Therefore, the role of Cypriot pharmacists (CPs) in primary CVD prevention is essential. This study aimed to explore both the existing and potential future roles of CPs in CVD prevention.</p><p><strong>Methods: </strong>A descriptive qualitative study employing structured interviews (SIs) was conducted. Initially, the CPs were identified through a list provided by the Cypriot Pharmaceutical Services. The researcher(s) then contacted CPs by telephone. Face-to-face interviews were scheduled based on the CP's availability. In total, 21 SIs were transcribed verbatim, coded, and analyzed thematically. SIs continued until data saturation was achieved.</p><p><strong>Findings: </strong>The findings are reported under the themes of pharmacists' knowledge and role, resources/tools available and training, communication and relations, and barriers. CPs expressed the need for training, and they are ready to have a more proactive role within the primary health care. The main barrier identified was the lack of responsiveness of the public and the lack of CP's time.</p><p><strong>Conclusion: </strong>CPs have the potential to actively participate in CVD prevention in Cyprus. CPs want to start offering primary CVD health services, with the smoking cessation being the first intervention.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 1","pages":"23-29"},"PeriodicalIF":1.0,"publicationDate":"2021-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/f0/JRPP-10-23.PMC8259602.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39210678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statin Type and Cancer Outcomes in Patients with Diabetes Type 2 and Solid Tumors. 他汀类药物与 2 型糖尿病和实体瘤患者的癌症预后
IF 0.8 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-05-13 eCollection Date: 2021-01-01 DOI: 10.4103/jrpp.JRPP_21_3
Alice C Ceacareanu, Shanria D Jolly, George K Nimako, Zachary A P Wintrob

Objective: Type 2 diabetes mellitus (T2DM) affects 10% of Americans and is associated with an increased incidence of cancer. Statins are first-line cholesterol-lowering medications in the treatment of hyperlipidemia. Several studies have demonstrated a relationship between statin use and reduced cancer incidence. We examined the cancer benefits of statin subtypes, with specific attention to disease-free survival (DFS) and overall survival (OS).

Methods: This retrospective review included adults with T2DM diagnosed with solid tumors at Roswell Park Cancer Institute in Buffalo, NY, USA (2003-2010). Individuals with gestational diabetes, incomplete records, or diagnosed with rare solid tumors were excluded. Follow-up began at the date of diagnosis and ended with the first confirmed recurrence, death, or loss of contact. Demographics were assessed by Chi-square, Kaplan-Meier survival analyses, and Cox proportional hazards regression.

Findings: Overall, 1102 patients met inclusion criteria, 52.1% of the study participants were female, and 578 participants (52.5%) died during the follow-up period which ranged from 0 to 156 months. Hydrophilic statin use was associated with improved DFS at 5-year follow-up (41.0% vs. 36.9%, P = 0.0077) compared to lipophilic statin use. Multivariate regression revealed that hydrophilic statins were associated with improved DFS (hazard ratio [HR]: 0.706, 95% confidence interval [CI]: 0.526-0.947) and OS (HR: 0.685, 95% CI: 0.503-0.934). Pravastatin was associated with improved OS (HR: 0.674, 95% CI: 0.471-0.964).

Conclusion: In patients with T2DM and cancer, hydrophilic statins, and pravastatin in particular, are associated with improved DFS as well as OS. Further research examining the cancer-specific effects of hydrophilic and lipophilic statins is needed to better understand their beneficial effects.

目的:10%的美国人患有 2 型糖尿病(T2DM),并且与癌症发病率的增加有关。他汀类药物是治疗高脂血症的一线降胆固醇药物。多项研究表明,他汀类药物的使用与癌症发病率的降低之间存在关系。我们研究了他汀类药物亚型对癌症的益处,特别关注无病生存期(DFS)和总生存期(OS):这项回顾性研究纳入了在美国纽约州布法罗市罗斯威尔帕克癌症研究所(Roswell Park Cancer Institute)确诊为实体瘤的 T2DM 成人患者(2003-2010 年)。不包括妊娠期糖尿病患者、记录不完整或诊断为罕见实体瘤的患者。随访从诊断之日开始,到首次确诊复发、死亡或失去联系时结束。通过Chi-square、Kaplan-Meier生存分析和Cox比例危险回归对人口统计学进行评估:共有1102名患者符合纳入标准,52.1%的研究参与者为女性,578名参与者(52.5%)在0至156个月的随访期间死亡。与使用亲脂性他汀类药物相比,使用亲水性他汀类药物可改善5年随访的DFS(41.0% vs. 36.9%,P = 0.0077)。多变量回归显示,亲水性他汀与DFS(危险比[HR]:0.706,95% 置信区间[CI]:0.526-0.947)和OS(HR:0.685,95% 置信区间[CI]:0.503-0.934)的改善相关。普伐他汀与OS的改善有关(HR:0.674,95% CI:0.471-0.964):结论:对于患有 T2DM 和癌症的患者,亲水性他汀类药物,尤其是普伐他汀,可改善 DFS 和 OS。为了更好地了解亲水性他汀类药物和亲油性他汀类药物对癌症的特异性作用,需要进一步开展研究。
{"title":"Statin Type and Cancer Outcomes in Patients with Diabetes Type 2 and Solid Tumors.","authors":"Alice C Ceacareanu, Shanria D Jolly, George K Nimako, Zachary A P Wintrob","doi":"10.4103/jrpp.JRPP_21_3","DOIUrl":"10.4103/jrpp.JRPP_21_3","url":null,"abstract":"<p><strong>Objective: </strong>Type 2 diabetes mellitus (T2DM) affects 10% of Americans and is associated with an increased incidence of cancer. Statins are first-line cholesterol-lowering medications in the treatment of hyperlipidemia. Several studies have demonstrated a relationship between statin use and reduced cancer incidence. We examined the cancer benefits of statin subtypes, with specific attention to disease-free survival (DFS) and overall survival (OS).</p><p><strong>Methods: </strong>This retrospective review included adults with T2DM diagnosed with solid tumors at Roswell Park Cancer Institute in Buffalo, NY, USA (2003-2010). Individuals with gestational diabetes, incomplete records, or diagnosed with rare solid tumors were excluded. Follow-up began at the date of diagnosis and ended with the first confirmed recurrence, death, or loss of contact. Demographics were assessed by Chi-square, Kaplan-Meier survival analyses, and Cox proportional hazards regression.</p><p><strong>Findings: </strong>Overall, 1102 patients met inclusion criteria, 52.1% of the study participants were female, and 578 participants (52.5%) died during the follow-up period which ranged from 0 to 156 months. Hydrophilic statin use was associated with improved DFS at 5-year follow-up (41.0% vs. 36.9%, <i>P</i> = 0.0077) compared to lipophilic statin use. Multivariate regression revealed that hydrophilic statins were associated with improved DFS (hazard ratio [HR]: 0.706, 95% confidence interval [CI]: 0.526-0.947) and OS (HR: 0.685, 95% CI: 0.503-0.934). Pravastatin was associated with improved OS (HR: 0.674, 95% CI: 0.471-0.964).</p><p><strong>Conclusion: </strong>In patients with T2DM and cancer, hydrophilic statins, and pravastatin in particular, are associated with improved DFS as well as OS. Further research examining the cancer-specific effects of hydrophilic and lipophilic statins is needed to better understand their beneficial effects.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 1","pages":"50-56"},"PeriodicalIF":0.8,"publicationDate":"2021-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/4a/JRPP-10-50.PMC8259595.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39215055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing the Effect of a Herbal-based Laxative (Goleghand®) and Polyethylene Glycol on Functional Constipation among Children: A Randomized Controlled Trial. 比较一种草药泻药(Goleghand®)和聚乙二醇对儿童功能性便秘的影响:一项随机对照试验。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-05-13 eCollection Date: 2021-01-01 DOI: 10.4103/jrpp.JRPP_20_133
Hosein Saneian, Saeedeh Ghaedi, Fatemeh Famouri, Majid Khademian, Najmeh Ahmadi, Mohammadreza Memarzadeh, Somayeh Sadeghi, Peiman Nasri

Objective: This study aimed to evaluate the effectiveness, safety, and document the reported adverse effect of a herbal-based laxative (Goleghand®) for the maintenance treatment of functional constipation in young children.

Methods: We conducted a randomized clinical trial from April 2019 to September 2020. Children aged 2-15 years with functional constipation defined according to the Rome IV criteria were eligible for study inclusion. Eligible children were randomly allocated to receive polyethylene glycol (PEG) or Goleghand®. The number and consistency of stools per day, painful defecation, abdominal pain, and fecal incontinence were reported weekly by parents. The statistical analyses were performed by determining means and standard deviations, t-test, Chi-square test, ANOVA repeated measures, and Fisher's exact test, with significance, accepted at the 5% level.

Findings: Sixty patients have been enrolled in the study. Parental satisfaction scores did not change significantly in either group or over the follow-up period. Our results showed that the effect of time (P < 0.001) and also the effect of group type (P = 0.01) on the number of fecal defecations was significant. The mean number of defecations increased first and then decreased significantly over time, but this decrease was more significant in the PEG group than in the Goleghand® group (P = 0.001). Furthermore, the effect of time on the fecal consistency score was significant (P = 0.047). The mean score of fecal consistency in both groups decreased over time.

Conclusion: Goleghand® was similar in efficacy to PEG for 8 weeks of pediatric functional constipation treatment in this randomized clinical trial. Goleghand® can be considered as a new herbal laxative drug for pediatric functional constipation.

目的:本研究旨在评估一种草药泻药(Goleghand®)用于幼儿功能性便秘维持治疗的有效性、安全性,并记录其报道的不良反应。方法:于2019年4月至2020年9月进行随机临床试验。2-15岁的儿童,根据Rome IV标准定义功能性便秘,符合纳入研究的条件。符合条件的儿童随机分配接受聚乙二醇(PEG)或Goleghand®治疗。父母每周报告每天大便的数量和稠度、排便疼痛、腹痛和大便失禁。统计分析通过确定均数和标准差、t检验、卡方检验、方差分析重复测量和Fisher精确检验进行,显著性在5%水平上接受。研究结果:60名患者参加了这项研究。父母满意度得分在两组和随访期间都没有显著变化。结果显示,时间对排便次数的影响显著(P < 0.001),组型对排便次数的影响显著(P = 0.01)。随着时间的推移,平均排便次数先增加后显著减少,但PEG组的减少比Goleghand®组更显著(P = 0.001)。此外,时间对粪便一致性评分的影响有统计学意义(P = 0.047)。两组的粪便稠度平均评分均随时间下降。结论:在这项随机临床试验中,Goleghand®在8周儿童功能性便秘治疗中的疗效与PEG相似。Goleghand®是一种治疗小儿功能性便秘的新型草药泻药。
{"title":"Comparing the Effect of a Herbal-based Laxative (Goleghand®) and Polyethylene Glycol on Functional Constipation among Children: A Randomized Controlled Trial.","authors":"Hosein Saneian,&nbsp;Saeedeh Ghaedi,&nbsp;Fatemeh Famouri,&nbsp;Majid Khademian,&nbsp;Najmeh Ahmadi,&nbsp;Mohammadreza Memarzadeh,&nbsp;Somayeh Sadeghi,&nbsp;Peiman Nasri","doi":"10.4103/jrpp.JRPP_20_133","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_20_133","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the effectiveness, safety, and document the reported adverse effect of a herbal-based laxative (Goleghand<sup>®</sup>) for the maintenance treatment of functional constipation in young children.</p><p><strong>Methods: </strong>We conducted a randomized clinical trial from April 2019 to September 2020. Children aged 2-15 years with functional constipation defined according to the Rome IV criteria were eligible for study inclusion. Eligible children were randomly allocated to receive polyethylene glycol (PEG) or Goleghand<sup>®</sup>. The number and consistency of stools per day, painful defecation, abdominal pain, and fecal incontinence were reported weekly by parents. The statistical analyses were performed by determining means and standard deviations, <i>t</i>-test, Chi-square test, ANOVA repeated measures, and Fisher's exact test, with significance, accepted at the 5% level.</p><p><strong>Findings: </strong>Sixty patients have been enrolled in the study. Parental satisfaction scores did not change significantly in either group or over the follow-up period. Our results showed that the effect of time (<i>P</i> < 0.001) and also the effect of group type (<i>P</i> = 0.01) on the number of fecal defecations was significant. The mean number of defecations increased first and then decreased significantly over time, but this decrease was more significant in the PEG group than in the Goleghand<sup>®</sup> group (<i>P</i> = 0.001). Furthermore, the effect of time on the fecal consistency score was significant (<i>P</i> = 0.047). The mean score of fecal consistency in both groups decreased over time.</p><p><strong>Conclusion: </strong>Goleghand<sup>®</sup> was similar in efficacy to PEG for 8 weeks of pediatric functional constipation treatment in this randomized clinical trial. Goleghand<sup>®</sup> can be considered as a new herbal laxative drug for pediatric functional constipation.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 1","pages":"43-49"},"PeriodicalIF":1.0,"publicationDate":"2021-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/8e/JRPP-10-43.PMC8259596.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39215053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Effectiveness of Plasmapheresis in Aluminum Phosphate Poisoning. 血浆置换治疗磷酸铝中毒的疗效。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-05-13 eCollection Date: 2021-01-01 DOI: 10.4103/jrpp.JRPP_21_27
Shiva Samsam Shariat, Shafeajafar Zoofaghari, Farzad Gheshlaghi
1. Tawfik HM. Recent advances in management of aluminium phosphide poisoning. QJM Int J Med 2020;113 Suppl 1:hcaa049.002. [doi: https://doi.org/10.1093/ qjmed/hcaa049.002]. 2. Elgazzar FM. Assessment of Intravenous lipid emulsion as an adjuvant therapy in acute aluminum phosphide poisoning: A randomized controlled trial. QJM Int J Med 2020;113 Suppl 1:hcaa049.001. [doi: https://doi.org/100.1093/ qjmed/hcaa049.001]. 3. Gheshlaghi F, Lavasanijou MR, Moghaddam NA, Khazaei M, Behjati M, Farajzadegan Z, et al. N-acetylcysteine, ascorbic acid, and methylene blue for the treatment of aluminium phosphide poisoning: Still beneficial? Toxicol Int 2015;22:40‐4. 4. Dorooshi G, Zoofaghari S, Mood NE, Gheshlaghi F. A newly proposed management protocol for acute aluminum phosphide poisoning. J Res Pharm Pract 2018;7:168-9. 5. Moghadamnia AA. An update on toxicology of aluminum phosphide. Daru 2012;20:25. 6. Tahergorabi Z, Zardast M, Naghizadeh A, Mansouri B, Nakhaei I, Zangouei M. Effect of aluminium phosphide (ALP) gas inhalation exposure on adipose tissue characteristics and histological toxicity in male rats. J Taibah Univ Sci. 2020;14:1317-25. Letter to the Editor
{"title":"Effectiveness of Plasmapheresis in Aluminum Phosphate Poisoning.","authors":"Shiva Samsam Shariat,&nbsp;Shafeajafar Zoofaghari,&nbsp;Farzad Gheshlaghi","doi":"10.4103/jrpp.JRPP_21_27","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_21_27","url":null,"abstract":"1. Tawfik HM. Recent advances in management of aluminium phosphide poisoning. QJM Int J Med 2020;113 Suppl 1:hcaa049.002. [doi: https://doi.org/10.1093/ qjmed/hcaa049.002]. 2. Elgazzar FM. Assessment of Intravenous lipid emulsion as an adjuvant therapy in acute aluminum phosphide poisoning: A randomized controlled trial. QJM Int J Med 2020;113 Suppl 1:hcaa049.001. [doi: https://doi.org/100.1093/ qjmed/hcaa049.001]. 3. Gheshlaghi F, Lavasanijou MR, Moghaddam NA, Khazaei M, Behjati M, Farajzadegan Z, et al. N-acetylcysteine, ascorbic acid, and methylene blue for the treatment of aluminium phosphide poisoning: Still beneficial? Toxicol Int 2015;22:40‐4. 4. Dorooshi G, Zoofaghari S, Mood NE, Gheshlaghi F. A newly proposed management protocol for acute aluminum phosphide poisoning. J Res Pharm Pract 2018;7:168-9. 5. Moghadamnia AA. An update on toxicology of aluminum phosphide. Daru 2012;20:25. 6. Tahergorabi Z, Zardast M, Naghizadeh A, Mansouri B, Nakhaei I, Zangouei M. Effect of aluminium phosphide (ALP) gas inhalation exposure on adipose tissue characteristics and histological toxicity in male rats. J Taibah Univ Sci. 2020;14:1317-25. Letter to the Editor","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 1","pages":"57"},"PeriodicalIF":1.0,"publicationDate":"2021-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/42/JRPP-10-57.PMC8259597.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39215056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of COVID-19 Treatment. COVID-19治疗综述。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-01-11 eCollection Date: 2020-10-01 DOI: 10.4103/jrpp.JRPP_20_72
Somayeh Sadeghi, Mahnaz Momenzadeh, Peiman Nasri, Mina Nickpour

Many contagious diseases, such as plague or cholera, played a role in changing the pathway of history. In this respect, although coronavirus was not as dangerous as novel diseases such as swine flu and Ebola, the spread and the power of coronavirus infiltration caused public fear across the world. Three viruses among coronaviruses have been epidemic during the recent years, including severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19 or new coronavirus. Respiratory droplets transmit the coronavirus through direct and indirect contact, and it can be transmitted through the contact in the case of remaining, the infected person's secretion on the surface. Based on the conducted studies on the treatment of COVID-19 disease, there is virtually no cure or vaccine for coronavirus infections yet. Those infected with Covid 19 are quarantined to prevent the outbreak of this disease. However, the researchers carried out different studies to investigate the impact of the various drugs on this virus, which in this study, we will examine the outline of this disease and the other conducted studies.

许多传染病,如鼠疫或霍乱,在改变历史进程方面发挥了作用。在这方面,虽然冠状病毒不像猪流感和埃博拉等新型疾病那样危险,但冠状病毒的传播和渗透能力引起了全世界公众的恐惧。近年来,冠状病毒中有三种病毒流行,分别是严重急性呼吸综合征(SARS)、中东呼吸综合征(MERS)和COVID-19或新型冠状病毒。呼吸道飞沫通过直接和间接接触传播冠状病毒,在表面残留感染者分泌物的情况下,可通过接触传播。根据对COVID-19疾病治疗的研究,目前还没有治愈新冠病毒感染的方法或疫苗。感染了Covid - 19的人被隔离,以防止这种疾病的爆发。然而,研究人员进行了不同的研究来调查各种药物对这种病毒的影响,在这项研究中,我们将研究这种疾病的概况和其他进行的研究。
{"title":"Review of COVID-19 Treatment.","authors":"Somayeh Sadeghi,&nbsp;Mahnaz Momenzadeh,&nbsp;Peiman Nasri,&nbsp;Mina Nickpour","doi":"10.4103/jrpp.JRPP_20_72","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_20_72","url":null,"abstract":"<p><p>Many contagious diseases, such as plague or cholera, played a role in changing the pathway of history. In this respect, although coronavirus was not as dangerous as novel diseases such as swine flu and Ebola, the spread and the power of coronavirus infiltration caused public fear across the world. Three viruses among coronaviruses have been epidemic during the recent years, including severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19 or new coronavirus. Respiratory droplets transmit the coronavirus through direct and indirect contact, and it can be transmitted through the contact in the case of remaining, the infected person's secretion on the surface. Based on the conducted studies on the treatment of COVID-19 disease, there is virtually no cure or vaccine for coronavirus infections yet. Those infected with Covid 19 are quarantined to prevent the outbreak of this disease. However, the researchers carried out different studies to investigate the impact of the various drugs on this virus, which in this study, we will examine the outline of this disease and the other conducted studies.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 4","pages":"169-174"},"PeriodicalIF":1.0,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/cb/JRPP-9-169.PMC8067900.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38919309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Assessment of Medication Adherence in Patients with Chronic Diseases in Tabuk, Kingdom of Saudi Arabia. 沙特阿拉伯王国Tabuk慢性疾病患者药物依从性评估
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-01-11 eCollection Date: 2020-10-01 DOI: 10.4103/jrpp.JRPP_20_97
Kousalya Prabahar, Maymonah Abdullah Albalawi, Lama Almani, Sarah Alenizy

Objective: Uncontrolled chronic diseases such as hypertension and diabetes mellitus can lead to severe complications. Poor adherence to medication is one of the important reasons, leading to complications for chronically diseased patients. We aimed to assess the trend toward medication adherence and the reasons for medication nonadherence in chronic disease patients in Tabuk city in Saudi Arabia.

Methods: A cross-sectional study was conducted at a tertiary care hospital in Tabuk, Saudi Arabia. Participants were selected and interviewed for information regarding their medication adherence. A medication adherence rating scale questionnaire was used to measure the level of adherence in study participants. The data were analyzed by the statistical package for the social sciences (SPSS) database 24.

Findings: Overall, 208 participants were involved in this study. Among these, 134 (64.4%) were female, and 74 (35.6%) were male. This study showed that 159 (76.44%) participants were adherent to their medications and nearly one-quarter of patients were nonadherent to their medications. No statistically significant differences were found between male and female patients toward their medication adherence. The primary intentional and nonintentional reason for nonadherence was side effects and forgetfulness, respectively.

Conclusion: Tailoring the therapy according to the individual need of the patients will maximize the patient's adherence toward medications.

目的:高血压、糖尿病等慢性疾病不加控制可导致严重并发症。服药依从性差是导致慢性病患者出现并发症的重要原因之一。我们旨在评估沙特阿拉伯Tabuk市慢性疾病患者药物依从性的趋势和药物不依从性的原因。方法:在沙特阿拉伯Tabuk的一家三级保健医院进行了一项横断面研究。参与者被选中并接受采访,以了解他们的药物依从性。使用药物依从性评定量表问卷来测量研究参与者的依从性水平。数据采用社会科学统计软件包(SPSS)数据库24进行分析。研究结果:总共有208名参与者参与了这项研究。其中女性134例(64.4%),男性74例(35.6%)。本研究显示,159名(76.44%)参与者坚持服药,近四分之一的患者不坚持服药。男性和女性患者在药物依从性方面没有统计学上的显著差异。不坚持治疗的主要故意和非故意原因分别是副作用和健忘。结论:根据患者的个性化需求定制治疗方案,可以最大限度地提高患者对药物的依从性。
{"title":"Assessment of Medication Adherence in Patients with Chronic Diseases in Tabuk, Kingdom of Saudi Arabia.","authors":"Kousalya Prabahar,&nbsp;Maymonah Abdullah Albalawi,&nbsp;Lama Almani,&nbsp;Sarah Alenizy","doi":"10.4103/jrpp.JRPP_20_97","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_20_97","url":null,"abstract":"<p><strong>Objective: </strong>Uncontrolled chronic diseases such as hypertension and diabetes mellitus can lead to severe complications. Poor adherence to medication is one of the important reasons, leading to complications for chronically diseased patients. We aimed to assess the trend toward medication adherence and the reasons for medication nonadherence in chronic disease patients in Tabuk city in Saudi Arabia.</p><p><strong>Methods: </strong>A cross-sectional study was conducted at a tertiary care hospital in Tabuk, Saudi Arabia. Participants were selected and interviewed for information regarding their medication adherence. A medication adherence rating scale questionnaire was used to measure the level of adherence in study participants. The data were analyzed by the statistical package for the social sciences (SPSS) database 24.</p><p><strong>Findings: </strong>Overall, 208 participants were involved in this study. Among these, 134 (64.4%) were female, and 74 (35.6%) were male. This study showed that 159 (76.44%) participants were adherent to their medications and nearly one-quarter of patients were nonadherent to their medications. No statistically significant differences were found between male and female patients toward their medication adherence. The primary intentional and nonintentional reason for nonadherence was side effects and forgetfulness, respectively.</p><p><strong>Conclusion: </strong>Tailoring the therapy according to the individual need of the patients will maximize the patient's adherence toward medications.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 4","pages":"196-201"},"PeriodicalIF":1.0,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/20/JRPP-9-196.PMC8067897.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38919312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
The COVID-19 Vaccine Saga: A Perspective. COVID-19 疫苗传奇:透视。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-01-11 eCollection Date: 2020-10-01 DOI: 10.4103/jrpp.JRPP_20_100
Shashank M Patil, Ramith Ramu
{"title":"The COVID-19 Vaccine Saga: A Perspective.","authors":"Shashank M Patil, Ramith Ramu","doi":"10.4103/jrpp.JRPP_20_100","DOIUrl":"10.4103/jrpp.JRPP_20_100","url":null,"abstract":"","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 4","pages":"218-219"},"PeriodicalIF":1.0,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/0a/JRPP-9-218.PMC8067902.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38839400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Common Opioids Involved in Drug Poisoning Presenting to the Emergency Department: A Cross-sectional Study. 急诊科常见阿片类药物中毒:一项横断面研究
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2021-01-11 eCollection Date: 2020-10-01 DOI: 10.4103/jrpp.JRPP_20_105
Nastaran Eizadi-Mood, Elham Haghshenas, Ali Mohammad Sabzghabaee, Ahmad Yaraghi, Ziba Farajzadegan

Objective: Opioids poisoning is of the most important cause of mortality. The objective of the study was to compare the demographic factors, clinical manifestations, and outcomes of the most common opioids involved in drug overdose presenting to the Emergency Department.

Methods: This cross-sectional study was conducted from October 2016 to March 2017 in the Clinical Toxicology Department of the main referral center of the university. All poisoning cases with common opioids were included in the study. Demographic factors, clinical manifestations, and outcome were recorded in a check list. ANOVA, Chi-square or Fisher's exact test, and binary logistic regression analysis were used for outcome prediction.

Findings: Two hundred and thirty six patients with opioids poisoning were evaluated during the study period. The most common opioids involved in poisoning were methadone (47.9%), tramadol (24.2%), and opium (21.6%). Patients with opium poisoning were older than others (P < 0.0001). The rate of suicide was more in the tramadol group, while the past history of psychological problems was more observed in the methadone group (P < 0.0001). Increasing age (odds ratio [OR], 1.05; 95% confidence interval [CI]: 1.02-1.09; P = 0.05) and addiction (P = 0.01; OR, 7; 95% CI: 1.55-31.52) was associated with an increased complications or death. Also patients with somatic disease had more chance of complications/death (P = 0.04; OR, 3.71; 95% CI: 1.06-12.97). Kind of opioids was not a predictive factor in the outcome of the patients with acute poisoning.

Conclusion: Age, addiction, and somatic disease should be considered as more important factors in outcome prediction with opioids poisoning, including opium, tramadol, and methadone.

目的:阿片类药物中毒是导致死亡的最主要原因。该研究的目的是比较急诊科最常见的阿片类药物过量的人口学因素、临床表现和结果。方法:本横断面研究于2016年10月至2017年3月在该大学主要转诊中心临床毒理学部进行。所有常见阿片类药物中毒病例均纳入研究。人口统计学因素、临床表现和结果记录在核对表中。结果预测采用方差分析、卡方检验或Fisher精确检验、二元logistic回归分析。结果:在研究期间对236例阿片类药物中毒患者进行了评估。最常见的阿片类药物中毒是美沙酮(47.9%)、曲马多(24.2%)和鸦片(21.6%)。鸦片中毒患者年龄大于其他患者(P < 0.0001)。曲马多组自杀率高于美沙酮组,美沙酮组有较多的心理病史(P < 0.0001)。年龄增加(优势比[OR], 1.05;95%置信区间[CI]: 1.02-1.09;P = 0.05)和成瘾性(P = 0.01;或者,7;95% CI: 1.55-31.52)与并发症增加或死亡相关。躯体疾病患者并发症/死亡的几率更高(P = 0.04;或者,3.71;95% ci: 1.06-12.97)。阿片类药物种类不是急性中毒患者预后的预测因素。结论:年龄、成瘾和躯体疾病是预测阿片类药物中毒(包括鸦片、曲马多和美沙酮)预后的更重要因素。
{"title":"Common Opioids Involved in Drug Poisoning Presenting to the Emergency Department: A Cross-sectional Study.","authors":"Nastaran Eizadi-Mood,&nbsp;Elham Haghshenas,&nbsp;Ali Mohammad Sabzghabaee,&nbsp;Ahmad Yaraghi,&nbsp;Ziba Farajzadegan","doi":"10.4103/jrpp.JRPP_20_105","DOIUrl":"https://doi.org/10.4103/jrpp.JRPP_20_105","url":null,"abstract":"<p><strong>Objective: </strong>Opioids poisoning is of the most important cause of mortality. The objective of the study was to compare the demographic factors, clinical manifestations, and outcomes of the most common opioids involved in drug overdose presenting to the Emergency Department.</p><p><strong>Methods: </strong>This cross-sectional study was conducted from October 2016 to March 2017 in the Clinical Toxicology Department of the main referral center of the university. All poisoning cases with common opioids were included in the study. Demographic factors, clinical manifestations, and outcome were recorded in a check list. ANOVA, Chi-square or Fisher's exact test, and binary logistic regression analysis were used for outcome prediction.</p><p><strong>Findings: </strong>Two hundred and thirty six patients with opioids poisoning were evaluated during the study period. The most common opioids involved in poisoning were methadone (47.9%), tramadol (24.2%), and opium (21.6%). Patients with opium poisoning were older than others (<i>P</i> < 0.0001). The rate of suicide was more in the tramadol group, while the past history of psychological problems was more observed in the methadone group (<i>P</i> < 0.0001). Increasing age (odds ratio [OR], 1.05; 95% confidence interval [CI]: 1.02-1.09; <i>P</i> = 0.05) and addiction (<i>P</i> = 0.01; OR, 7; 95% CI: 1.55-31.52) was associated with an increased complications or death. Also patients with somatic disease had more chance of complications/death (<i>P</i> = 0.04; OR, 3.71; 95% CI: 1.06-12.97). Kind of opioids was not a predictive factor in the outcome of the patients with acute poisoning.</p><p><strong>Conclusion: </strong>Age, addiction, and somatic disease should be considered as more important factors in outcome prediction with opioids poisoning, including opium, tramadol, and methadone.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 4","pages":"202-207"},"PeriodicalIF":1.0,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/63/JRPP-9-202.PMC8067901.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38839403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Research in Pharmacy Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1